Germany’s pilot markets will decide Europe’s next five years
Dr. Miriam Keller, Drug Policy Researcher, Berlin
We asked twelve leading voices in policy, medicine, investment and cultivation for three predictions about the year ahead, and the reasoning behind each one.
What 36 predictions add up to: where the panel agrees, and where it splits.
Pilot markets and large clinical trials will give regulators real data for the first time.
New markets will open through medicine and exports, not adult-use retail.
Fewer, larger operators. Mergers will outpace new entrants.
CBD and minor cannabinoids will compete on evidence and quality, not marketing.
The panel’s sharpest split. Five expect real change in 2027; seven do not.
Four sectors. Three predictions each. One year ahead.
Dr. Miriam Keller, Drug Policy Researcher, Berlin
Jonathan Reyes, Regulatory Attorney, Washington, D.C.
Ploy Srisuk, Former Government Policy Adviser, Bangkok
Dr. Hannah Moore, Pain Medicine Specialist, Toronto
Prof. Kenta Sato, Pharmacologist, Tokyo
Dr. Lucía Herrera, Cannabinoid Scientist, Bogotá
Daniel Whitford, Managing Partner, New York
Pieter de Vries, Equity Analyst, Amsterdam
Grace Liu, Chief Executive, Sydney
Tomás Becker, Hemp Cooperative Founder, Lucerne
Aisha Rahman, Head of Product Formulation, London
Isabel Ortega, Master Grower, Montevideo
Cannabis is regulated differently in every market. This year’s outlook draws on five regions.
No expert paid to appear, and every financial interest is disclosed on their page.
Read our methodologyCannabis Industry Outlook 2027 is an independent editorial project by two cannabis publications.
About the projectAn independent resource on cannabinoid science, products and regulation.
Visit CBD LibraryA daily briefing on the global cannabis industry for professionals and investors.
Visit Cannabis Newsletter